HC Wainwright raised its price forecast for Arcus Biosciences Inc.
(NASDAQ:RCUS), citing the aggressive push into 1L clear cell renal cell carcinoma (ccRCC) development.
Arcus Expands Casdatifan Development Strategy In First-Line ccRCC In the first quarter press release, the company said its development strategy is designed to generate evidence to secure casdatifan as a backbone therapy in ccRCC.
Read Also: What's Going On With Arcus Biosciences Stock On Wednesday?
The company is aggressively executing on a holistic strategy to embed casdatifan into the treatment paradigm, including in combination with the most commonly used regimen in the 1L setting, anti-PD-1 plus anti-CTLA-4.
